Evidence map›Paper›PMID 40076843›Full record

ArticleInternational journal of molecular sciences2025

Identification and Molecular Mechanism of Novel α-Glucosidase Inhibitory Peptides from the Hydrolysate of Hemp Seed Proteins: Peptidomic Analysis, Molecular Docking, and Dynamics Simulation.

Zhang Mengyuan, Chen Chen, Wei Feng, Zhao Ning, Yang Wanyu, Zhang Tianrong, Ren Guoyan, Qiu Zhijun, Zhang Bin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhang MengyuanCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.
Chen ChenCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.
Wei FengCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.
Zhao NingAcademy of Military Medical Sciences, Beijing 100850, China.
Yang WanyuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.
Zhang TianrongCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.
Ren GuoyanCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.ORCID 0000-0001-9745-521X
Qiu ZhijunCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.
Zhang BinCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, China.ORCID 0000-0003-2811-7158

Funding

National Natural Science Foundation of China 31701536National Natural Science Foundation of China 82200738Student Research Training Program (SRTP) of Henan Province 202410464070
6 · The paper itself

Abstract

There is a growing demand for natural and potent α-glucosidase inhibitors due to the rising prevalence of diabetes. In this study, newly identified α-glucosidase inhibitory peptides were identified from the tryptic hydrolysate of hemp seed proteins based on peptidomics and in silico analysis. A total of 424 peptides, primarily derived from four cupin-type-1 domain-containing proteins, were identified, and 13 ultimately were selected for validation based on their higher PeptideRanker scores, solubility, non-toxicity, and favorable ADMET properties. Molecular docking revealed that these 13 peptides primarily interacted with α-glucosidase via hydrogen bonding and hydrophobic interactions. Among them, three novel peptides-NPVSLPGR (-8.7 kcal/mol), LSAERGFLY (-8.5 kcal/mol), and PDDVLANAF (-8.4 kcal/mol)-demonstrated potent α-glucosidase inhibitory activity due to their lower binding energies than acarbose (-8.1 kcal/mol), the first approved α-glucosidase inhibitor for type 2 diabetes treatment. The molecular mechanism analysis revealed that the peptides NPVSLPGR and LSAERGFLY inhibited α-glucosidase by simultaneously blocking substrate entry through occupying the entrance of the active site gorge and preventing catalysis by binding to active sites. In contrast, the peptide PDDVLANAF primarily exerted inhibitory effects by occupying the entrance of the active site gorge. Molecular dynamics simulation validated the stability of the complexes and provided additional insights into the molecular mechanism determined through docking. These findings contribute essential knowledge for the advancement of natural α-glucosidase inhibitors and offer a promising approach to effectively manage diabetes.

Indexed as

alpha-GlucosidasesCannabisGlycoside Hydrolase InhibitorsPeptidesPlant ProteinsProtein HydrolysatesSeedsMolecular Docking SimulationMolecular Dynamics SimulationProteomicsalpha-GlucosidasesGlycoside Hydrolase InhibitorsPeptidesPlant ProteinsProtein Hydrolysates?-glucosidase inhibitory peptideshemp seed proteinsin silico analysismolecular dockingmolecular dynamicspeptidomics

Identifiers

PMID40076843
PMCPMC11899805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.